Market Chatter: Novo Nordisk Urged by Shareholders to Develop New Medicines, Pursue Acquisitions

MT Newswires Live

Sep 21

Novo Nordisk (NVO) is facing shareholder calls to develop new medicines and pursue acquisitions so that it could lower its dependence on its popular weight-loss treatments, the Financial Times reported Sunday, citing the company's investors.

The Danish pharmaceutical giant's chief executive, Mike Doustdar, is under pressure to demonstrate that Novo can regain ground lost to key rival Eli Lilly (LLY) in the obesity drug market, according to the report.

Novo will discuss topics, including research and development, at its capital markets day scheduled for Monday, the company said in a statement e-mailed to MT Newswires.

Novo shares were down 6.1% in premarket activity Monday.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/news/2669154261"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2669154261\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2669154261?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-21 17:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2669154261","market":"sg","top_or_hot":-1,"title":"Market Chatter: Novo Nordisk Urged by Shareholders to Develop New Medicines, Pursue Acquisitions","media":"MT Newswires Live","content":"<html><body><p> Novo Nordisk (NVO) is facing shareholder calls to develop new medicines and pursue acquisitions so that it could lower its dependence on its popular weight-loss treatments, the Financial Times reported Sunday, citing the company's investors.</p><p>The Danish pharmaceutical giant's chief executive, Mike Doustdar, is under pressure to demonstrate that Novo can regain ground lost to key rival Eli Lilly (LLY) in the obesity drug market, according to the report.</p><p>Novo will discuss topics, including research and development, at its capital markets day scheduled for Monday, the company said in a statement e-mailed to MT Newswires.</p><p>Novo shares were down 6.1% in premarket activity Monday.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Market Chatter: Novo Nordisk Urged by Shareholders to Develop New Medicines, Pursue Acquisitions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarket Chatter: Novo Nordisk Urged by Shareholders to Develop New Medicines, Pursue Acquisitions\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-21 17:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Novo Nordisk (NVO) is facing shareholder calls to develop new medicines and pursue acquisitions so that it could lower its dependence on its popular weight-loss treatments, the Financial Times reported Sunday, citing the company's investors.</p><p>The Danish pharmaceutical giant's chief executive, Mike Doustdar, is under pressure to demonstrate that Novo can regain ground lost to key rival Eli Lilly (LLY) in the obesity drug market, according to the report.</p><p>Novo will discuss topics, including research and development, at its capital markets day scheduled for Monday, the company said in a statement e-mailed to MT Newswires.</p><p>Novo shares were down 6.1% in premarket activity Monday.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2669154261","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2669154261","pubTimestamp":1789984022,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Novo Nordisk  is facing shareholder calls to develop new medicines and pursue acquisitions so that it could lower its dependence on its popular weight-loss treatments, the Financial Times reported Sunday, citing the company's investors.The Danish pharmaceutical giant's chief executive, Mike Doustdar, is under pressure to demonstrate that Novo can regain ground lost to key rival Eli Lilly  in the obesity drug market, according to the report.Novo will discuss topics, including research and development, at its capital markets day scheduled for Monday, the company said in a statement e-mailed to MT Newswires.Novo shares were down 6.1% in premarket activity Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","NVOX":"2倍做多NVO ETF-Defiance","PPH":"VanEck Pharmaceutical ETF","THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","OZEM":"Roundhill GLP-1 & Weight Loss ETF","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","NVOC":"Corgi NVO 2x Daily ETF","NVO":"诺和诺德","BK4599":"减肥药","BK4532":"文艺复兴科技持仓","BK4007":"制药","NVOH":"Novo Nordisk A/S B Shares ADRhedged","BK4588":"碎股","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1"},"translate_title":"市场传闻：股东敦促诺和诺德开发新药，寻求收购","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVOH":0.6,"NVOX":0.6,"NVO":1.95,"PPH":0.6,"OZEM":0.6,"NVOC":0.6,"THNR":0.6},"content_text":"Novo Nordisk (NVO) is facing shareholder calls to develop new medicines and pursue acquisitions so that it could lower its dependence on its popular weight-loss treatments, the Financial Times reported Sunday, citing the company's investors.The Danish pharmaceutical giant's chief executive, Mike Doustdar, is under pressure to demonstrate that Novo can regain ground lost to key rival Eli Lilly (LLY) in the obesity drug market, according to the report.Novo will discuss topics, including research and development, at its capital markets day scheduled for Monday, the company said in a statement e-mailed to MT Newswires.Novo shares were down 6.1% in premarket activity Monday.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}